Biosyngen Announces FDA Fast Track Designation For BST02 In Treatment Of Liver Cancer
SINGAPORE, Feb. 1, 2024 /PRNewswire/ -- Biosyngen is proud to announce that its latest groundbreaking product, BST02, has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA) for the treatment of all types of...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Clinical Trials | Food and Drug Administration (FDA) | Liver | Pharmaceuticals | Singapore Health | Urology & Nephrology